Skip to main content
NPHC logo

Nutra Pharma Corp. (NPHC) Stock Price & Analysis

Nutra Pharma Corp. (NPHC) — price $0.0002 (0.00%), as of the Nov 18, 2026 trading session; market cap $1.43M.

Educational signal · not a buy or sell recommendation · How to read this

$0.0002 $0.00 (0.00%) Market Cap $1.43M

Nutra Pharma Corp. · NPHC

Nutra Pharma Corp. is a biopharmaceutical company focused on acquiring, licensing, and commercializing products for pain management, neurological disorders, cancer, and autoimmune diseases. Their product line includes Nyloxin and Pet Pain-Away, targeting both human and animal pain relief.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • IMCC · IM Cannabis Corp. · 22 /100
  • UPC · Universe Pharmaceuticals Inc. · 32 /100
  • YCBD · cbdMD, Inc. · 23 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0002
Change on the day0.00%
52-week range$0.0001 – $0.005
Market capitalisation$1.43M
Shares traded on the day75

Price & events

Other perspectives

Council score for Nutra Pharma (NPHC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Gross Margin Moderate

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Nutra Pharma (NPHC), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nutra Pharma Corp. (NPHC) is the company analyzed here. It employs 6 people and is led by Michael D. Flax. In Q2 FY2026 it reported revenue of $34,463 and net income of -$4M. The market values it at $1.43M.

2 · Latest results

What do the latest results show for Nutra Pharma (NPHC)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $34,463.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$34,463-$4M-$0.0005 (diluted)
Q1 FY2026$48,214-$459,675-$0.0001 (diluted)
Q4 FY2025$54,066-$488,526-$0.0001 (diluted)
Q3 FY2025$70,242-$523,520-$0.0001 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Nutra Pharma (NPHC)?

Short answer · as of

The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 30.3% · current ratio 0.02 · free-cash-flow yield -73.3%.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
3
Purchases
5
Sales
0
Other transactions
7

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NPHC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NPHC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Nutra Pharma Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the NPHC research dossier (written Mar 15, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What are the main risks for NPHC?

Nutra Pharma Corp. faces several risks, including intense competition from larger pharmaceutical companies, regulatory hurdles in obtaining FDA approvals, and potential product liability claims. The company's limited financial resources and dependence on a small number of products further amplify these risks.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.